Cue Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
Cue Biopharma, Inc., a Delaware corporation and emerging growth company, filed this Current Report on Form 8-K on November 14, 2022. The filing details the entry into a Material Definitive Agreement regarding a private placement offering of equity securities.
Key Financial Metrics and Transaction Details
The Company entered into a Securities Purchase Agreement to raise capital through a private placement. Key financial terms include:
- Gross Proceeds: Approximately $30.0 million.
- Net Proceeds: Approximately $28.2 million (after deducting placement agent fees).
- Securities Issued:
- 7,656,966 shares of Common Stock.
- 1,531,440 Pre-Funded Warrants (in lieu of shares for certain investors).
- Warrants to purchase up to 9,188,406 additional shares.
- Pricing:
- Common Stock/Pre-Funded Warrant price: $3.265 per share (or $3.2649 for Pre-Funded Warrants).
- Warrant Exercise Price: $3.93 per share (or $3.9299 for Pre-Funded Warrants).
- Warrant Terms: Warrants are exercisable immediately and expire five years after the closing date. Pre-Funded Warrants do not expire.
The filing does not provide current revenue, profit, cash flow, or debt metrics, as this is a transaction-specific report rather than a periodic financial statement.
Material Changes and Agreements
On November 14, 2022, the Company executed the following material agreements:
- Securities Purchase Agreement: Established the terms for the private placement with accredited investors. Piper Sandler & Co. acted as lead placement agent, with Public Ventures LLC as co-placement agent.
- Registration Rights Agreement: The Company agreed to file a registration statement for the resale of the securities within 20 days of closing. The Company is responsible for all registration fees and expenses.
- Liquidated Damages: If the registration statement is not filed or declared effective within specified timelines, the Company must make pro rata payments to investors equal to 1% of the aggregate amount invested per 30-day period.
Outlook, Risks, and Contingencies
Closing Conditions: The Offering is expected to close on or about November 16, 2022, subject to customary closing conditions.
Risk Factors: The filing highlights significant risks including:
- Limited operating history, limited cash, and a history of losses.
- Uncertainty regarding the ability to achieve profitability.
- Potential setbacks in research and development, including negative preclinical or clinical trial results.
- Reliance on regulatory approvals from the FDA and other governmental bodies.
- Dependence on third-party licensors, collaborators, and suppliers.
- Need to secure adequate future financing.
Forward-Looking Statements: The report contains forward-looking statements regarding the expected closing of the Offering and future business strategies, which are subject to risks and uncertainties.
Investor Verification Checklist
- Verify the actual closing date of the Offering (expected November 16, 2022) and confirmation of net proceeds received.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and Registration Rights Agreement (Exhibit 10.2) for specific covenants and indemnification terms.
- Monitor the filing of the registration statement for resale of the securities within the required 20-day window post-closing.
- Assess the impact of the new share issuance and warrants on existing shareholder dilution.
- Review the Company's most recent Form 10-K or 10-Q for updated cash position and burn rate to evaluate runway post-offering.